----item----
version: 1
id: {52C0899B-C887-442D-AB16-77F060F5A245}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/03/25/BioDelivery plunges on failed diabetic neuropathy gel study
parent: {CE0B93D3-20EA-4DFE-BC95-04ADDD6DB633}
name: BioDelivery plunges on failed diabetic neuropathy gel study
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 9128fe5f-e052-4605-8cba-22b6369c7300

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 38

{B3122C5E-FF3F-438A-9C93-1B54DC1286A5}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 59

BioDelivery plunges on failed diabetic neuropathy gel study
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 59

BioDelivery plunges on failed diabetic neuropathy gel study
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1996

<p>Shares of BioDelivery Sciences plunged 33% on 30 March after the firm said a Phase III trial revealed that its painful diabetic neuropathy topical gel Clonidine was no better than placebo &ndash; results that caught the company off guard.</p><p>"Based on the results of our previously announced positive interim analysis, this outcome was unexpected," said Dr Andrew Finn, BDSI's executive vice president of product development.</p><p>Shares of the Raleigh, North Carolina-based biotech closed at $10.51 on 30 March, down $3.38, or 24.3%.</p><p>The interim analysis data showed a difference versus placebo of -0.94, with a standard deviation of 2.2, which was close to BDSI's study assumption of -1.0 and 1.8, respectively, and very similar to the prior Phase II study conducted by the firm's licensor Arcion, Dr Finn explained.</p><p>Based on the interim analysis, the company added about 80 patients to the study. </p><p>"However, this added cohort of patients performed very differently than those assessed in the interim analysis, which lead to our outcome," Dr Finn said. </p><p>BDSI CEO Dr Mark Sirgo noted the company encountered similar challenges in its early clinical development work with its chronic pain drug BEMA Buprenorphine, which ultimately was successful in meeting the primary endpoints in two pivotal studies. </p><p>"Leveraging this experience and the aspects of this study that we believe are encouraging, we are optimistic that we can achieve a similar outcome with Clonidine topical gel," Dr Sirgo declared.</p><p>The company noted that certain secondary endpoints in the Phase III Clonidine topical gel study showed statistically significant improvement over placebo and insisted the drug demonstrated a strong safety profile.</p><p>Dr Finn said BDSI was "confident&rdquo; the data from the Phase III study &ldquo;will provide us with the necessary information to enhance patient entry criteria, patient recruitment and site selection."</p><p><p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 245

<p>Shares of BioDelivery Sciences plunged 33% on 30 March after the firm said a Phase III trial revealed that its painful diabetic neuropathy topical gel Clonidine was no better than placebo &ndash; results that caught the company off guard.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 59

BioDelivery plunges on failed diabetic neuropathy gel study
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150325T170000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150325T170000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150325T170000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028285
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 59

BioDelivery plunges on failed diabetic neuropathy gel study
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

357490
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042323Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

9128fe5f-e052-4605-8cba-22b6369c7300
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042323Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
